Some previous studies have linked the diabetes medication pioglitazone to bladder cancer. However a new study – including more than one million people in six populations worldwide – has found no link between either pioglitazone or rosiglitazone (also known as Avandia) and bladder cancer.
The new study is published in Diabetologia (the journal of the European Association for the Study of Diabetes), and is by Dr Samira Bell, Professor Helen Colhoun and Mr Danny Levin, University of Dundee, UK, and colleagues from the International Diabetes and Cancer Research Collaboration.
You can read the full article here.
